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Primary cutaneous eD30-positive (anaplastic) large 
T -cell lymphomas and lytnphomatoid papulosis are 
closely related types of cutaneous T-celllymphoma with 
a favorable prognosis. The neoplastic T cells in these 
conditions have the phenotype of activated eD3 +, en4 +, 
ens-, en30+ skin homing T cells, but their normal 
counterpart bas not yet been defined. To further charac-
terize the cellular origin of the neoplastic T cells, skin 
biopsies from 14 patients with primary cutaneous en30-
postttve (anaplastic) large T-cell lymphomas, nine 
patients with lymphmnatoid papulosis, and six patients 
with primary cutaneous en30-negative pleomorphic 
large T-cell lymphomas were stained with monoclonal 
antibodies against cytotoxic cell-associated molecules 
granzytne B and T-cell restricted intracellular antigen. 
In nine of nine lymphomatoid papulosis and in 10 of 
14 en30-positive primary. cutaneous large T-cell 
lymphotnas, expression of granzyme B and T-cell 
P rimary cutaneo us CD30-positi ve large T-cell lymphomas (LTCL) have recently been recognized as a distinct type of cuta neous T-celllymphoma (CTCL). They are chaTac-terized clini cal.l y by presentation with solitary or localized skm les10ns, a r.~vorable response to therapy, and an 
exce!Jent prognosis (5-y survival 90'Y,,), and histologically by a prolifeTa-
tion of large, mostly a.iuplastic T cells and expression of the CD30 
antigen on more than 75% of the neoplastic T cells (.Beljaards et a/, 
1993; Will emze eta!, 1994). ln contrast, prima1y cutaneous pl eomorphi c 
or immunoblastic LTCL that do not express the CD30 antigen often 
have a poor prognosis with an estimated 5-y survival of = 15% 
(Belj aards e/ a/, 1989). There is a close relationship between primary 
cutaneous CD30-positive LTC L and lymphomatoid papulosis (LyP) 
(Wil.lemze and Beljaa rds, J 993; Willemze et a/, 1994) . LyP is a distin ct 
type of CTCL represented by a chroni c, recurrent self-h ealing papular 
eruption that is characterized by its benign clinical course despite th e 
histologic appearance of a malignant lymphom.a with clonal CD30-
positive tumor cells (Maccaulay, "1968; Wil.lemze et al, 1982; Kaudewitz 
eta/, 1986). In both conditions the neoplastic ce lls have the phenotype 
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restricted intracellular antigen by variable numbers of 
neoplastic cells was found. Expression of granzyn"Ie B by 
the neoplastic en30-positive T cells was confirmed by 
double- staining for granzyme B and en30 (three cases) 
and by the detection of granzyme B mRNA using RNA 
in situ hybridization (one case) . In most cases equal 
nutnbers of granzyme-B -positive and T- cell restricted 
intracellular antigen positive tum.or cells were observed. 
In five of six en30- negative primary cutaneous large 
T - cell lymphomas the neoplastic cells did not express 
these proteins, whereas in one case a sporadic positive 
tumor cell was found . These results demonstrate that, in 
contrast to primary cutaneous eD30-negative pleo-
morphic large T- cell lymphomas, the neoplastic cells in 
most primary cutaneous en30-positive (anaplastic) large 
T-cell lyn"Iphon"Ias and lytnphomatoid papulosis have a 
unique en4 +, ens-, cytotoxic T- cell phenotype. KeJI 
words: cutaneous T- ceU l)lmphoma/ cytotoxic T cell! granzJime 
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of activated CD4 +, CDS-, CD30+ skin homing T cells (Kaeli n et a/, 
1985; Kaudewitz et a/, 1 986), but the p1:ecise normal cellular counterpart 
of these cells has not yet been defined. 
Recently, monoclonal antibodi es (Mo.Ab) against components of 
the cytotoxic granules presen t in th e cytoplasm of cytotoxic lympho-
cytes have become available. These cytotoxic molecules include perforin 
(Lichtenheld et a/, 1988), the serin e proteases granzyme A and B 
(Krahenbuhl eta/, 1988; Griffiths and Muel.l er, J 991), and the T-ce!J 
res tticted intracel.luJar antigen (TIA-1) (Anderso n et a/, 1990; Anderson, 
1995) . Recently, the role of granzymes in target cell death has been 
extensively studied. Experiments with granzyme .B knockout mice 
have shown that granzyme B plays a cru cia.l ro le in cytotoxic T 
lymphocyte and natural ki.l.l er cell- mediated target cell death (H eusel 
et a/, 1994). It is now thought that granzyme B directly activates the 
execu tion pathway of apoptosis in the target ce ll by ac ti vating its 
endogenous apoptotic machinery (Da.rmon eta /, 1995). Alth ough TlA-
1 has also been implicated in target ceLl apoptosis its di rect role is stiLl 
unclear (Anderson, 1995) . Because these molecules are largely restricted 
to (activa ted) cytotoxic T cells and na tural killer cells, expression of 
these cytotoxic molecules by the neoplastic cells of malignant 
lymphomas strongly suggests that th ese ce!Js aTe the neoplastic equiva-
lents of subsets of cytotoxic T cells or natmal killer ceUs. 
To further characterize th e cellular ori gin of n eoplastic T ce!Js in 
the primaty cutaneous CD30-positi ve T-cell proliferations, in the 
present study skin biopsies from 14 patients with primaty cutan eous 
CD30-positive (anaplastic) LTCL, nine patients with LyP, and six 
patients with a primary cutaneous CD30-negative LTCL were investi -
gated for expression of the cytotoxic lymphocyte-associa ted proteins 
gnnzyme Band TlA-1. 
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Table I. Granzyme B and TIA-1 expression by neoplastic cells in patients w ith lymphom,atoid papulosis, primary cutaneous 
CD30-positive large T-cell lymphomas, and priJ:nary cutaneous CD30-negative large T-celllymphornas 
N eoplastic cells 
Pad ent Diagnosis T i l" GrB7'' TIA- 11! C D3' CD4' CDS' 
I LyP 40/60 +++ +++ + + 
2 LyP 20/80 ++ nd + + 
3 LyP 5/ 95 + + :t + 
4 LyP 5/ 95 ++ + + + 
5 LyP 10/90 occ occ + + 
6 LyP 10/90 + + nd nd 
7 LyP 5/ 95 + nd + + 
8 LyP 5/95 + nd + + 
9 LyP 5/95 + + + + 
10 CD 30+ ALC L 50/SO ++ + + + + 
11 C D30+ ALC L 25/75 + +++ + + 
12 C D30+ ALCL 20/80 + + + + 
13 CD 30+ PMLCd 95/5 occ occ + + 
14 CD 30+ ALC L 70/30 + + + + 
15 C D30+ ALCL 50/ 50 + + + + 
16 C D30+ ALCL 95/5 + nd ± + 
"17 CD30+ ALCL 90/10 occ + + + 
"18 C D30+ ALCL 20/80 + + + + 
19 CD30+ ALCL 90/10 occ occ ± + 
20 C D30+ ALCL 40/60 + 
21 CD30+ ALCL 90/10 + + 
22 C D30+ PMLC 90/10 + 
23 C D30+ ALC L 80/20 nd + 
24 C D30- PMLC 95/ 5 occ occ + + 
25 CD30- PMLC 80/20 + + 
26 CD 30- PMLC 95/5 + + 
27 C D30- PMLC 60/40 + + 
28 CD30- PMLC 80/20 + ± 
29 CD 30- PMLC 90/10 + 
" T he ra tio between the percent:tge of neoplastic T cells and th e percentage of reactive inAammatory cdJs as described in i\ltaten'af ami !VIetlwds. 
b Scored on par:~ fiin -embedded m:1 teri :li : -, no positive nl!oplast ic cell s; occ, <5% positive neoplastic cells; +, 5-25!Xl positive ncoplas1tic cells; + +. 25-50% positive neoplastic cells; 
and + + +, > SO% positive ncopbsti c cells. 
r Scon:·d on fresh fi·own nwtc rial: +. all rwopbstic ccUs stained positive; :±: , loss of marker expression by :t v:t ri:lble number of neoplastic cells;-. no staining of neoplastic T ce lls. 
d PM LC, pleomorphic, medium , ami large. 
MATERIALS AND M ETHO DS 
Patients Paraffin-embedded skin spec imens fi·01n 14 cases of prima1y 
cutaneous C D30-pos itive LT CL, six cases of primary cutaneous C D30- negati ve 
LTC L, and n.i ne cases of LyP were selec ted fi·om the tissue bank of the 
Du tc h C utan eous Lymphoma Worki ng Group. T he diagnosis WJS based on a 
combination o f clinical, . histologic, and im.rnunopheno typi cal ctiteria, as 
described prev·iously (Wi \Jemze ct a/, 1994) . 
Patients with LyP (Table I, patients 1-9) had a typical clinical presentation 
and cl ini cal course with chronic, recurrent, self- healing papular or papulonecrotic 
ski n lesions (Maccaulay, "\96S) . Histological\y, the skin biopsies showed the 
characteristi c features of LyP type A with variable numbers of C D30-positive 
large (anaplastic) T cel\s within a cons iderable inflanm1atory infi ltrate o f small 
lymphocytes, histi ocytes , neutrophils, and/ or eosinophils. In al.l cases most 
neoplasti c T cel\s expressed C D3, CD4, and CD 30, but never C DS amigen 
(Table I). 
Patients with a primaiy cutaneous C D30-positive LTCL (patients 10-23) 
presemed with a single or few locali zed nodules or tumors. Most cases showed 
cohesive sheets and/o r large clusters o f large CD30-pos iti ve tumor cells with 
o nly a few adm.ixed reactive lymphocytes . In some cases, however, a considerable 
admixture with in8ammato1y cells was observed, .illusm1ting the close resemb-
lance between these C D30-positive LTC L and LyP. In 12 o f 14 cases the 
nt!o plasti c cells demonstrated a characteristic morphology, whereas two cases 
(13 and 22) were composed of large pleomorphic (nona napbsti c) T cells. In all 
cases, however, at least 75% of the ttlmor cells expressed CD30 antigen 
(Beljaards cr a/, 1993) . In nearly all cases the neopl:lsti c cells showed a C D3+, 
CD4 +, cos- phenotype (Table I) with a variable loss o f pan T-cell markers, 
as assessed on fi·ozen sections of another part of th.e same biopsy, or another 
biopsy obta ined at the same time. 
All six cases with a prima1y cutaneous C D30-nega tive LTCL (pati ents 24-
29) had the morphologic characteristics of a pleomorphic medium-sized/ large 
cell lymphoma (updated \(iel classifi catio n) (S tansfield ct a/, 1988). T hese 
lymphomas showed a proli feration o f medium-sized to large pleomorphic T 
cells w ith relatively fe w admixed inAammatory cel.ls (Table I). Tbe neoplastic 
cel.ls expressed the CD3 +, C D4-I+, CD S-, C D30- phenotype (Table I). N one 
of these 20 primaty cutaneous LTCL had prior or concurrent mycosis fun goides 
or another type of CT C L. In all 20 pati ents extensive stagi ng procedures, 
including physical examination, total and differential blood cell counts, chest 
radiography, computerized abdominal to mograp hy, and bone marrow biopsy, 
had f.1iled to demonstrate extrac utaneous disease at the time of presentation. 
Imn~unobistochen~istry lmmun osta.ining on fonnalin-fixed, paraffin -
embedded secti ons w.ith MoAb against gran zyme B (GrB7) (Kummer ct a/, 
1993, 1995) and T IA- 1 (Coulter, Hialeah, FL) (Anderson et a/, 1990) was 
perfo rmed, using a streptavidin-b.iotin - perm,idase technique following antigen 
retri eval with microwave heating, as described previously (Oudejans et a/, 1996) . 
In addition, sections were stained with the MoAb Ber- H2/ CD 30 and polyclonal 
C D3 (both from DAJ(O, Glostrup, Dem11ark) , M oAb Leu-3 directed against 
C D4 (Beckton Dickinson, San Jose , C A) , and MoAb 144B, a MoAb directed 
against C DS (a generous gift fi·om Dr. Mason, Oxford, U.K.). 
In three cases (patients 3, 4, and 12) , double-staining was perfo rmed for 
granzyme B and C D30. Bti efiy, after boiling in a citrate bufte r for 10 min , 
sections were incubated with GrB7 for 1 It , washed, and .incubated with biotin-
labeled goa t-anti -mouse IgG2a (Southern Bio technology, BinTiingham , AL) . 
Subsequently, sections were incubated with peroxidase-conjuga ted streptavidin. 
The peroxidase was visualized by incubation fo r 10 min in 0.2 mg diam.inobenz.i-
dine per m], 0.002% H20z, 0.07% NiClz in 50 mM Tris-1-lC I, pH 7.6, 
resulting in a diaminobenzidine-nickel precipitate . After blocking tl1e remaining 
peroxidase activ ity with 0.3% H zOrmethanol for 15 min, secti ons were 
incubated with BerH2 for 1 h, washed, and incubated witl1 biotin-labeled goa t-
anti-mouse IgG 1 (DAKO) , fo llowed by in cubation w ith the streptavidin- bioti n-
horseradish peroxi dase complex. Visuali zation was done with diaminobenzidine/ 
H 20 2, resulting in a clear brown sibmal for CD 30. Subsequently, silver 
enhancement of the di aminobenzidine-nickel precipitate was pe1formed as 
described previously (Merchentaler er a/, 1989), resulting in a black granular 
signal for granzyme B . N ega tive contw ls included simultaneously processed 
sections with omission o f the GrB7 and C D30 specifi c antibodi es, respectively. 
Granzyme B RNA i11 situ. hybridization (RISH) To confirm that granzyme 
B pro tein was produced by tumor cells, IUSH was perfonned in one case 
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(patient 1 ), in which granzyme-B-positive tumor ce'lls were detected by 
immunohistochemistty. The RJSH procedure has been descnbed 111 detatl 
elsewhere Oiwa et. al, 1993) . T he sense and anti-sense riboprobes used were 
generated by ;, vitro transcriptio n of a 350-bp Psl'l restriction fragment of 
granzyme 13 eDNA (nucleotides 1-350) (Trapani et a/, 1988) cloned 111 a pGEM 
7zf(+) vector (P romega, Mad ison, W I). The mRNA quahty 111 the tlssue s!Jdes 
was checked by R ISH using ~2-micro gl.obulin as a control target mRNA. 
Interpretation of immnnohistochcmical staining Slides were scored 
independently by two experi enced dermatopa thologists. The pcrcenwge of 
tumo r cells was estimated to the tota l numbers of mononuclear cells. In LyP 
and the CD30-positive LTCL the large CD30-positive (a naplasti c) cells were 
considered as the neoplastic component. In CD30-negative LTCL morphologic 
distinction between neoplastic cells and admixed reactive lymphocytes ca n 
sometimes be difficul t. Because all. CD30-negati ve LTCL were composed 
predominantly of large pleomorpl'Li c T cells, however, morphologic distincti on 
fi·om reactive (s mall) cells yielded no pro'b.lc m in these cases. 
T he percentage of neoplastic cells positive for granzyme B and T IA-1 were 
scored as foll ows: - , no positive ceLls; occasional, < 5% posltlve cell s; +, 5-25'% 
positive cells; + + , 25-50% positive cell s; and + + +, > SO% positive 
cells (Table I). 
RESULTS 
CD30-positive neoplastic cells express the CTL-associated pro-
teins granzyme Band TIA-1 In ali nin e cases ofLyP the neoplastic 
cells showed a clear granula r cytoplasmic staining for both granzyme 
B (Fig la) and T IA-1. ln general, the percentage of T IA-1-positive 
CD30-positive tumo r cells was equal to the percentage of gran zyme-
B-positive cells, as demo nstrated by exarnination of seL; aJ sections 
(Table I). T he percentage of positive tumor cells ranged from 10 to 
90% of the total number of tumor cells. Evidence that granzyme B is 
in deed produced by the CD30-positive tumor cells was based on th e 
double-staining experiments showing co-localization of granzyme B 
and CD30 in th e neoplastic T cells (Fig lc), as well as by the 
observation o f identical distributi on patterns of granzym.e B mRNA and 
protein, as demonstrated by R ISH (Fig lb) and immunohistochemistry 
(Fig la), respectively. 
[n 10 of 14 primary cutaneous CD30-positive LTCL CD 30-positi ve 
neoplastic cells showed a granular cytop.lasmic staining for gra nzym e 
B and/or T lA-1 (Fig ld) . In nearly aU cases tested, equa.l proportrons 
of granzyme-B- and T IA-1-positive CD30-positive tumor cells were 
found. In some cases granzyme-B- and TIA-1.-positive mi toses were 
easily detected . As in· LyP, the percentage of granzyme-B-positive 
tumor cells va ri ed substantially, ranging from 5% to even 80% of the 
total number of tumor cells. In m ost cases (eight of 10) , however, only 
a rninority (~ 10%) of the tumor cel.ls were granzyrne B and/or 
TlA-1 positive. 
ln five of six primary cuta11 eous CD30-negative pleomorphic LTCL 
granzyme B and T lA-1 were only expressed by a few scattered reactive 
T cells, but not by the neoplastic T cells (Table I ; Fig le,j) . In one 
case (patient 24), however, a small proportion (< 5%) of the large 
pleomorphic T cells expressed bo th granzyme B and TIA-1. 
In ali 29 biopsies studied reactive lymphocytes expressing granzyme 
B and T IA-1 were present, acting as a positive control. Although the 
proportion of admixed inflammatory ceUs varied considerably between 
the three gr.·oups of CTCL studied, in ali three groups granzym e-B-
and T IA-1-positive ce!Js made up 10-50% of th e total number of 
inflammatory cells. In general the number of TIA-1 -positive reactive 
lymph ocytes was equal to or higher than the number of gr.·anzyme-B-
positive lymph ocytes. Although no double-staining was perfonned, 
the disttibution pattern of these reactive cells exp ressing granzyme B 
and T lA-1 was very similar to that o f smaU CD 8-positive cells in 
adjacent histologic sections, suggesting that most of these cells 
represented (activated) CD 8-positive T cells. 
DlSCUSSION 
ln the present study we studied a large gro up of primary cutaneo:rs 
CD30-positi ve lymphoprolifera tions for the presence of a cytotoXJc 
phenotype by immLm ostaining with MoAb against cytotoxic cell -
associated proteins granzyme B and T IA-1. Expression of granzyme B 
and T IA-1 was fo und in variable proportions of the CD30-positive 
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mostly anaplastic tumor ce Lls in nin e of nine patients with LyP and in 
10 of 14 patients w ith C D30-positive LTCL, but not in any of the 
patients with CD30-negati ve pleomorphic LTCL, except for one of 
six cases, in which few tumor cells expressed these anngens. T he 
presence of granzyme B in the neoplastic CD 30-positive T cells was 
confi rmed by doubl e-staining fo r granzyme B and CD 30, as well as 
by the detection of granzyme B mRNA in these cells usin g R ISH . 
Taken together, in 19 of 23 (82'.!1',) primary cutaneo us CD30-posm ve 
lymphoproli fe rations the neoplastic cells expressed cytotoxic cell-
associated protei ns, suggestin g a derivation fi·om eith er natura.! killer 
cells or cytoxic T cell s. B eca use th e neoplastic cells in these primary 
cutaneous CD 30- positive LTCL generally demonstrate clo nal T-cell 
receptor gene rearrangements (Ba nerj ee et a/, 1991; M acGrogan et a/, 
1996), and express CD3 and CD4 but not CD56 (Wrllemze et a/, 
unpublish ed observa tion), a derivation from. natural killer cel.ls can be 
excluded. T he observation that these neoplasti c cells uni formly express 
a CD4 phenotype impli cates that th e neoplastic cells in th ese primary 
cutaneous CD30-positive lymphoproliferations should be considered 
as the neoplastic counterparts of a CD4-positive cytotoxic T-ceU subset. 
T he existence of CD4-positive cytotoxic T cells has been well 
established (Ha hn et a/, 1995). T hese cells express perforin , gra nzyme 
B, and TIA- 1, either constitutively or upon activation (Liu eta /, 1989; 
Anderson eta/, 1990; Susskind et a/, 1996), and m ediate cytotoxiciry 
in a major histocompatabili ty co mplex class ll restricted way (Hahn 
et a/, 1995; Susskind ct a/, 1996). In peripheral blood fi:om healtl1y 
individuals 3-8% of the CD4-positive T lymphocytes constitutively 
express TlA-1 , probably defining a pop ulation with cytolytic potentia l 
(Anderson et a/, 1990) . Although the biologic ro le of these cells m 
normal immune homeostasis has yet to be defined, an immun omodula-
tory role, by killing amigen presenting cells, has been suggested (Hahn 
eta/, 1995) . 
In four primary cutaneous CD 30-positi ve LTCL no granzyme B 
and/or TIA-1 expression co uld be detec ted. Whether these cases are 
derived from precursor cytotoxic T cells, w hi ch do not yet express 
cytotoxic granules, or are the neoplastic counterparts of another T-cell 
subset is as ye t unknown. Both granzyme-B/TlA-1 -positive and 
gr.·a nzyme-B/TIA-1-negative C D30-positive LTCL nearly always 
expressed CD3 and CD4 antigens, but never CD S, and stro ngly 
expressed the activation markers CD30 and HLA-DR (data not shown) , 
sugges ting tl1at the differential staining for granzyme B and TlA-1 rs 
not re lated to the ph enotype or sta te of ac tiva tio n of th e neoplastic cells. 
There are o nly a few reports on the expression of cytotoxic molecules 
in malignant lymphomas, and studies on large groups of primary 
cutaneous lymphomas have not yet been pub.lished. M.ost recentl y, 
Krenacs et a/ reported expression of perfm;n and T IA-1 in 70% and 
67% of primaty noncutaneous CD 30-positive anaplastic large cell 
lymphomas (ALCL) ofT or null cell phenotyp e (.Krenacs et a/, 1997). 
T he three primary cutaneous CD30-positive ALCL in this study 
expressed neither peLforin nor T IA-1. In a study of Foss et al (1996) 
over 90% of primary noncutaneous ALCL expressed perforin rnRNA 
and gran zym e B . In contrast to the results of Krenacs et a/, perforin 
transcripts were detected in aU three primary cutaneous C D30-positi ve 
ALCL iJl cluded in this study; expression of granzym e B was not 
investiga ted . In contras t to the results of Foss et a/, de Bruin et al 
reported expression of granzyme B in only two of 16 nodal ALCL, 
and in one of six pLimary cutaneous CD30-positive ALCL (de B rum 
et a/, 1994). This difference ca n be explained, as in the latter study 
lymphomas were considered positi ve if m.ore than 50% of the tumor 
cells expressed gr.·a nzym e B, whereas in the study of Foss et a/ a case 
was considered positive when there was unequivocal staining of 
neoplastic cells irrespec ti ve of th eir number. 
T he few published repo rts on mostly extranodal malignant 
lymphomas expressing cytotoxic antigens suggest that these o ften site-
restricted lymphomas are neoplastic equivalents of different subsets of 
cytotoxic cells with th e.ir own site-specifi c morphology and imrnuno-
phenotype. For instance, nasal lymphomas expressing granzyme B and 
perfoL;n generally show a CD3- , CD 56+ or a CD3 +,CDS + phenorype, 
and are therefore considered as th e neoplastic counterparts of e1ther 
natural killer ce!Js or activated CD 3 +, CDS+ cytotoxic T cells involved 
in the normal immune defense at this site (de Bruin et a!, 1994; Mori 
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Figure 1. Granzyme B and TIA-1 are expressed by neoplastic cells in LyP and in primary cutaneous CD30-positive anaplastic large T-cell 
lymphoma. Sections were stained with a MoAb agoinst granzyme B (n, c,e) or with :1 MoAb agoinst TIA-1. (dJ). In addition, a double-staining fo r granzyme B 
ond CD30 was perfo rmed (c). Granzyrne .B expression by neoplasti c cells was confirmed by lUSH to r granzyme B (b) . (••) Granzyme B protein expression in 
lymphomatoid papulosis; (b) granzyme .B mR.NA expression in lymphomatoid papulosis; (c) lymphomatoid papulosis mined for both granzyme B :md CD30 [lmgc 
nrrowhcnd, a CD 30-positive tumor cell (brown) ex-presses granzyme B (black); small OI"IV111hend, reactive granzyme-B- pos itive, CD30-negative CTL]; (d) TlA- 1 
pro tein express ion in CD30-positive primary cuta neous LTCL; (e) gronzyme B protein expression in CD30-negotive primaty cutaneous LTCL (s111all nrmwhend, 
granzyme-B-positive, reactive cytotoxic T cell); (I) T lA- 1 prote in expression in CD 30-negative p1i mary cutaneous LTCL (s 111nll nrmw!Jcnd, TlA-1-positive, reactive 
CTL) . Sca le bars , (a,c--:fJ 10 ~lm ; (b) 17 ~lrn. 
ct a/, 1996). Gastrointestinal lymphomas associated with glu ten-sensitive 
enteropathy expressing granzyn1.e Band T !A-l generally have a CD3 +, 
C D4-, CDS + phenotype, sometim es a CD4- , cos- or a CD4 +, 
cos- ph enotype, but rarely a CD3--, C D56+ ph enotype, suggesti ng 
that most lymphom as in this group are derived from different subsets 
of activated cytotoxic T cells (de Bruin cr a/, 1994; 1997). With respect 
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to the group of CD30-positive ALCL, the primary noncutaneous 
ALCL expressing cytotoxic antigens show considerable vatiation in 
phenotype. T he studies of both Foss et al and Krenacs et a/ included 
CD4+, CDS-; CD4-, CDS+ ; CD4-, CDS- ; and, in th e study of 
Krenacs et a/, some CD4 + , CDS + cases . This heterogeneity may 
suggest that these primary noncutaneous ALCL expressing cytotoxic 
antigens are detived from different types of cytotoxic T cells. In 
contrast to these primary non cutaneous CD30-positive ALCL, primary 
cutaneous CD30-positive lymphoproliferations uniforml y express a 
CD4 +, CD S- phenotype, and may be considered as the neoplastic 
counterparts of a unique CD4 +, CDS- cytotoxic T-cell subset. 
1?1e authors tlwuk A 11ja 1-lorstmau and Joost OudejaiiS for l11eir excellent tee/mica / 
assistance. 
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